Harvard Bioscience Reports $56.7M FY25 Net Loss Driven by Goodwill Impairment; Revenue Declines
HBIO sits 77% above its 52-week low of $0.281.
Summary
Harvard Bioscience announced its fourth quarter and full-year 2025 financial results, reporting a significant net loss of $56.7 million for the full year, primarily driven by a $48.0 million goodwill impairment charge in Q1 2025. Full-year revenue declined to $86.6 million from $94.1 million in 2024, and Q4 revenue also fell to $23.7 million from $24.6 million year-over-year. While adjusted EBITDA showed improvement for both periods, the substantial net loss and revenue contraction indicate operational challenges. The company provided Q1 2026 guidance with revenue between $20.0 million and $22.0 million and full-year 2026 guidance projecting 2-4% revenue growth, contingent on a strategic shift to translational science and new product innovation. Traders will be watching for execution on this strategic pivot and the ability to reverse revenue declines and improve profitability.
At the time of this announcement, HBIO was trading at $0.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.7M. The 52-week trading range was $0.28 to $0.95. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.